Amendment to Collaboration Agreement between OSI Pharmaceuticals, Inc. and Structural GenomiX, Inc.

Summary

OSI Pharmaceuticals, Inc. and Structural GenomiX, Inc. have agreed to amend their existing Collaboration Agreement dated August 1, 2003. The amendment allows OSI Pharmaceuticals to increase its representation on the Joint Steering Committee to three members, with one being a non-voting representative. This change is effective immediately upon acceptance by Structural GenomiX, as confirmed by the signed letter.

EX-10.24 33 a12108orexv10w24.txt EXHIBIT 10.24 EXHIBIT 10.24 OSI Pharmaceuticals, Inc. 58 South Service Road, Suite 110 Melville, NY 11747 ###-###-#### F ###-###-#### www.osip.com [(OSI)(TM) PHARMACEUTICALS LOGO)] January 11, 2004 VIA FEDERAL EXPRESS Sean A. McCarthy, D.Phil. Vice President, Business Development Structural GenomiX, Inc. 10505 Roselle Street San Diego, CA 92121 Re: Collaboration Agreement dated August 1, 2003 between Structural GenomiX, Inc. and OSI Pharmaceuticals, Inc. Dear Sean: This letter confirms acceptance by Structural GenomiX of an amendment to Section 2.8(b) of the above-referenced Collaboration Agreement whereby effective immediately, OSI Pharmaceuticals shall have the option to increase its membership on the Joint Steering Committee (JSC) to three (3) representatives, one of whom shall be a non-voting representative. Please indicate your agreement by signing two copies and returning one copy to my attention at OSI Pharmaceuticals, Inc. Regards, /s/ Barbara A. Sawitsky Barbara A. Sawitsky Director, Corporate Development Agreed and Accepted: STRUCTURAL GENOMIX, INC. Name: /s/Herbert G. Mutter ---------------------------------------- Title: Vice President, Finance --------------------------------------- Date: 2/26/04 ---------------------------------------- Copy: N. Gibson L. Arnold A. Castelhano N. Pegg